|75.13||-6.26||-7.69%||Vol 1.59M||1Y Perf -40.94%|
|Aug 9th, 2022 16:00 DELAYED|
|- -||0.84 1.12%|
|Target Price||116.89||Analyst Rating||Moderate Buy 1.59|
|Potential %||55.58||Finscreener Ranking||★★★★★ 60.36|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★★★★ 63.73|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★★★★ 81.33|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||32.58||Earnings Rating||Strong Sell|
|Market Cap||5.86B||Earnings Date||4th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-2.23|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.43M|
|Avg. Monthly Volume||1.58M|
|Avg. Quarterly Volume||1.99M|
CRISPR Therapeutics AG (NASDAQ: CRSP) stock closed at 81.39 per share at the end of the most recent trading day (a -0.01% change compared to the prior day closing price) with a volume of 1.53M shares and market capitalization of 5.86B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 410 people. CRISPR Therapeutics AG CEO is Samarth Kulkarni.
The one-year performance of CRISPR Therapeutics AG stock is -40.94%, while year-to-date (YTD) performance is 7.4%. CRSP stock has a five-year performance of 363.23%. Its 52-week range is between 42.511 and 142.64, which gives CRSP stock a 52-week price range ratio of 32.58%
CRISPR Therapeutics AG currently has a PE ratio of 22.50, a price-to-book (PB) ratio of 2.88, a price-to-sale (PS) ratio of 442.20, a price to cashflow ratio of 13.40, a PEG ratio of 2.32, a ROA of 13.99%, a ROC of 14.32% and a ROE of 15.78%. The company’s profit margin is 34.07%, its EBITDA margin is 36.40%, and its revenue ttm is $13.90 Million , which makes it $0.18 revenue per share.
Of the last four earnings reports from CRISPR Therapeutics AG, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-2.23 for the next earnings report. CRISPR Therapeutics AG’s next earnings report date is -.
The consensus rating of Wall Street analysts for CRISPR Therapeutics AG is Moderate Buy (1.59), with a target price of $116.89, which is +55.58% compared to the current price. The earnings rating for CRISPR Therapeutics AG stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CRISPR Therapeutics AG has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CRISPR Therapeutics AG has a Buy technical analysis rating based on Technical Indicators (ADX : 24.23, ATR14 : 5.38, CCI20 : 87.77, Chaikin Money Flow : 0.11, MACD : 2.41, Money Flow Index : 54.07, ROC : 1.80, RSI : 42.98, STOCH (14,3) : 60.96, STOCH RSI : 1.00, UO : 55.06, Williams %R : -39.04), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CRISPR Therapeutics AG in the last 12-months were: James R. Kasinger (Option Excercise at a value of $0), Lawrence Otto Klein (Option Excercise at a value of $0), Samarth Kulkarni (Option Excercise at a value of $91 858), Tony W. Ho (Option Excercise at a value of $0)
Thu, 28 Jul 2022 03:26 GMT CRISPR Therapeutics: Why Its Growth Potential Could Get Cheaper- TipRanks. All rights reserved.
Tue, 12 Jul 2022 12:45 GMT Crispr Therapeutics AG (CRSP) Gets a Buy Rating from William Blair- TipRanks. All rights reserved.
Tue, 12 Jul 2022 04:16 GMT Crispr Therapeutics AG (CRSP) Receives a Buy from JMP Securities- TipRanks. All rights reserved.
Mon, 27 Jun 2022 14:56 GMT Crispr Therapeutics AG (CRSP) Receives a Buy from William Blair- TipRanks. All rights reserved.
Mon, 13 Jun 2022 12:15 GMT Crispr Therapeutics AG (CRSP) Gets a Buy Rating from Chardan Capital- TipRanks. All rights reserved.
Mon, 13 Jun 2022 10:35 GMT Crispr Therapeutics AG (CRSP) Gets a Buy Rating from Needham- TipRanks. All rights reserved.
Mon, 13 Jun 2022 04:15 GMT Crispr Therapeutics AG (CRSP) Gets a Buy Rating from JMP Securities- TipRanks. All rights reserved.
Fri, 08 Apr 2022 19:55 GMT Crispr Therapeutics AG (CRSP) Receives a Buy from Brookline Capital Markets- TipRanks. All rights reserved.
Tue, 01 Mar 2022 05:35 GMT Crispr Therapeutics AG (CRSP) Received its Third Buy in a Row- TipRanks. All rights reserved.
Sun, 09 Jan 2022 09:31 GMT CRSP: Investors Pumped by Unique Price Point, Intriguing Pipeline- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.